
Opinion|Videos|April 7, 2025
18-Month Retrospective Claims Analysis Study Information on Ruxolitinib
Author(s)Gary M. Owens, MD , Lawrence Eichenfield, MD
Panelists discuss how the 18-month retrospective claims analysis of ruxolitinib revealed sustained efficacy in atopic dermatitis management, with significant reductions in disease flares, healthcare utilization, and concomitant medication use compared to conventional therapies, while maintaining a consistent safety profile across diverse patient populations and disease severities.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
The biosimilars market is projected to nearly double — here's where the growth is coming from
2
Journavx helped most patients avoid opioids after surgery, a recent study found
3
Endometriosis increases the risk of Type 2 diabetes
4
Cholinergic urticaria: Hives caused by heat and what can be done about it
5














